Guidance for market authorization requirements for COVID-19 drugs: Quality and manufacturing requirements
Données et ressources
Info additionnelle
| Champ | Valeur |
|---|---|
| Source | |
| Version | |
| Producteur | |
| Courriel de l'auteur | |
| Mainteneur | |
| Courriel du mainteneur | |
| Data Level | |
| Agreement Required | |
| Purpose Constraints | |
| Redistribution Allowed | |
| AI Training Allowed | |
| Data Steward | |
| Title (French) | Lignes directrices sur les exigences relatives aux autorisations de mise en marché des médicaments contre la COVID-19 : Exigences de qualité et de fabrication |
| Update Frequency | as_needed |
| Geographic Scope | [] |
| Criticality Level | [] |
| Sensitivity Level | unrestricted |
| Langue | |
| Contact Person | |
| Contact Email | |
| Dictionnaire de données | |
| Open Canada Date Published | 2021-10-29 00:00:00 |
| Open Canada Date Modified | |
| Open Canada Subject | ["health_and_safety"] |
| Open Canada Keywords | {"fr": ["COVID-19", "médicaments COVID-19", "exigences d'autorisation de mise sur le marché", "médicament fabriqué", "vendu", "processus réglementaire", "exigences de fabrication", "exigences de qualité"], "en": ["COVID-19", "COVID-19 drugs", "market authorization requirements", "drug manufactured", "sold", "regulatory process", "manufacturing requirements", "quality requirements"]} |
| Open Canada Collection | publication |
| Principal Organization | |
| Reference Data | |
| Official Source |